MDM2 and cancer: Additionally, given the likelihood of a multimodal therapeutic approach for highly aggressive cancers such as TNBC, additional synergistic studies with current TNBC therapeutics will be helpful to evaluate clinical-stage MDM2 inhibitors in adjuvant therapies of TNBC, which has not scientifically been addressed yet.